BRPI0720211A2 - Derivado de indanona, composição, e, uso de uma composição - Google Patents

Derivado de indanona, composição, e, uso de uma composição

Info

Publication number
BRPI0720211A2
BRPI0720211A2 BRPI0720211-3A2A BRPI0720211A BRPI0720211A2 BR PI0720211 A2 BRPI0720211 A2 BR PI0720211A2 BR PI0720211 A BRPI0720211 A BR PI0720211A BR PI0720211 A2 BRPI0720211 A2 BR PI0720211A2
Authority
BR
Brazil
Prior art keywords
composition
indanone derivative
indanone
derivative
Prior art date
Application number
BRPI0720211-3A2A
Other languages
English (en)
Inventor
Laxminarayan Bhat
Prabhu Prasad Mohapatra
Original Assignee
Reviva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reviva Pharmaceuticals Inc filed Critical Reviva Pharmaceuticals Inc
Publication of BRPI0720211A2 publication Critical patent/BRPI0720211A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0720211-3A2A 2006-12-11 2007-12-11 Derivado de indanona, composição, e, uso de uma composição BRPI0720211A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86949906P 2006-12-11 2006-12-11
PCT/US2007/025392 WO2008073452A1 (en) 2006-12-11 2007-12-11 Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0720211A2 true BRPI0720211A2 (pt) 2013-12-24

Family

ID=39512052

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720211-3A2A BRPI0720211A2 (pt) 2006-12-11 2007-12-11 Derivado de indanona, composição, e, uso de uma composição

Country Status (13)

Country Link
US (2) US8247563B2 (pt)
EP (1) EP2114166A4 (pt)
JP (1) JP2010512328A (pt)
CN (1) CN101626688A (pt)
AU (1) AU2007333586A1 (pt)
BR (1) BRPI0720211A2 (pt)
CA (1) CA2672212A1 (pt)
IL (1) IL198921A0 (pt)
MX (1) MX2009005795A (pt)
NZ (1) NZ578187A (pt)
RU (1) RU2478619C2 (pt)
WO (1) WO2008073452A1 (pt)
ZA (1) ZA200904211B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007108011A2 (en) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Process for the preparation of highly pure donepezil
PL2343284T3 (pl) * 2008-10-02 2015-08-31 Korea Res Inst Chemical Tech Pochodne uracylu i herbicydy zawierające te pochodne
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2365316B1 (es) 2010-03-18 2012-09-06 Consejo Superior De Investigaciones Científicas (Csic) Nuevos derivados de propargilamina con capacidad neuroprotectora para el tratamiento de las enfermedades de alzheimer y parkinson.
EP2575815A4 (en) 2010-06-04 2013-12-25 Albany Molecular Res Inc GLYCIN TRANSPORTER 1 INHIBITORS, METHODS OF MAKING THE SAME, AND USES THEREOF
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
WO2014008629A1 (en) * 2012-07-10 2014-01-16 Suzhou Shangzhi Biotech Limited Novel derivatives of donepezil
CN103787954B (zh) * 2012-10-26 2016-01-20 中国科学院上海药物研究所 一类氟取代的环状胺类化合物及其制备方法、药物组合物和用途
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
BR102013030928A2 (pt) * 2013-11-29 2015-09-22 Cristália Produtos Químicos Farmacêuticos Ltda processo para a preparação de cloridrato de donepezila formas i e iii; e de um composto intermediário do mesmo
TW201625601A (zh) 2014-07-02 2016-07-16 諾華公司 噻吩-2-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625586A (zh) 2014-07-02 2016-07-16 諾華公司 環己烯-1-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625584A (zh) * 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
MX384391B (es) 2015-05-22 2025-03-14 Agenebio Inc Composiciones farmacéuticas de levetiracetam de liberación extendida.
CN105859732B (zh) * 2016-04-11 2018-04-06 浙江海正药业股份有限公司 制备ad‑35的工艺
JP6899120B2 (ja) * 2016-10-12 2021-07-07 株式会社ナノエッグ アセチルコリンエステラーゼ(AChE)阻害剤
WO2019108226A1 (en) 2017-12-01 2019-06-06 Hewlett-Packard Development Company, L.P. Computer devices to establish network connections
EP3946299A4 (en) * 2019-03-29 2022-11-23 Taiwanj Pharmaceuticals Co., Ltd. BENZENE DERIVATIVES EXTENDED WITH PERIPHERAL ALKYL AND ALKENYL CHAIN EXTENDED AND PHARMACEUTICAL COMPOSITIONS THEREOF

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
FR2484415A1 (fr) 1980-06-13 1981-12-18 Pharmindustrie Nouveaux derives de l'indene, procedes pour leur preparation, et leur utilisation comme medicaments
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP0535496A1 (en) * 1991-09-25 1993-04-07 Hoechst-Roussel Pharmaceuticals Incorporated (1-Indanon-2yl)methylpiperidines, intermediates and a process for their preparation and their use as medicaments
US5272158A (en) * 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4439822A1 (de) 1994-11-08 1996-08-29 Bayer Ag Verfahren zur Herstellung von Benzyl-piperidylmethyl-indanonen
ES2123307T3 (es) * 1995-02-24 1999-01-01 Kao Corp Sal de amonio cuaternario, metodo para la fabricacion de la misma y su utilizacion como composicion suavizante.
PL197306B1 (pl) * 1995-12-15 2008-03-31 Pfizer Nowe pochodne 4-[2-(3,4-dimetoksybenzoilo)allilo]piperydyny
SK285312B6 (sk) * 1996-06-07 2006-10-05 Eisai Co., Ltd. Polymorf (III) donepezil hydrochloridu, spôsob jeho výroby a terapeutický prostriedok s jeho obsahom
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
US6252081B1 (en) 1998-01-16 2001-06-26 Eisai Co., Ltd. Process for production of donepezil derivative
IL125809A (en) 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
DE60014043T2 (de) * 1999-03-03 2005-09-29 Eisai Co., Ltd. Flouride von 4-substituierten piperidin-derivaten
DE60034577T2 (de) 1999-09-01 2007-12-27 Eisai R&D Management Co., Ltd. In 4-stellung substituierte piperidinderivate
CN1240384C (zh) * 1999-11-04 2006-02-08 美国爱科赛尔制药有限公司 石杉碱经皮给药制剂
NZ521576A (en) 2000-02-29 2005-06-24 Mitsubishi Pharma Corp Novel cyclic amide derivatives
JPWO2003061658A1 (ja) 2002-01-22 2005-05-19 エーザイ株式会社 インダノン誘導体を含有するシグマ受容体結合剤
EA200401289A1 (ru) * 2002-04-01 2005-04-28 Кадила Хелзкэр Лимитед Новые противоинфекционные соединения, способы их получения и фармацевтические композиции, содержащие эти соединения
US7148354B2 (en) 2002-07-24 2006-12-12 Dr. Reddy's Laboratories Limited Process for preparation of donepezil
US6953856B2 (en) 2003-02-12 2005-10-11 Usv, Limited Process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCI)
AU2003247158A1 (en) * 2003-07-01 2005-01-21 Hetero Drugs Limited Preparation of intermediates for acetyl cholinesterase inhibitors
EP1677783A2 (en) * 2003-10-08 2006-07-12 Nicholas Piramal India Limited Fibrinogen receptor antagonists and their use
WO2005076749A2 (en) 2004-02-11 2005-08-25 Jubilant Organosys Limited A novel process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine
JP2008280248A (ja) 2005-11-02 2008-11-20 Eisai R & D Management Co Ltd アルツハイマー型痴呆症治療薬塩酸ドネペジルのプロドラッグ
NZ569532A (en) 2006-01-04 2010-11-26 Cipla Ltd Process and intermediate for preparation of donepezil

Also Published As

Publication number Publication date
US8580822B2 (en) 2013-11-12
RU2478619C2 (ru) 2013-04-10
EP2114166A1 (en) 2009-11-11
MX2009005795A (es) 2009-06-08
NZ578187A (en) 2012-05-25
AU2007333586A1 (en) 2008-06-19
ZA200904211B (en) 2010-03-31
CN101626688A (zh) 2010-01-13
CA2672212A1 (en) 2008-06-19
EP2114166A4 (en) 2011-05-25
IL198921A0 (en) 2010-02-17
US20120252842A1 (en) 2012-10-04
WO2008073452A8 (en) 2009-01-22
RU2009126589A (ru) 2011-01-20
US20080153878A1 (en) 2008-06-26
WO2008073452A1 (en) 2008-06-19
JP2010512328A (ja) 2010-04-22
US8247563B2 (en) 2012-08-21

Similar Documents

Publication Publication Date Title
BRPI0720211A2 (pt) Derivado de indanona, composição, e, uso de uma composição
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0908792A2 (pt) Composição, e, uso de uma combinação
BRPI0821165A2 (pt) Uso de uma composição
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
DK1884242T3 (da) Farmaceutisk sammensætning omfattende lurasidon
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0716327A2 (pt) Composto de fenilpropionamida e uso
BRPI1014316A2 (pt) composição, e, uso de uma composição
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0906253A2 (pt) Composição de dentifrício, e, uso de uma composição
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
BRPI0720234A2 (pt) Composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2284 DE 14/10/2014.